Results 151 to 160 of about 5,511 (190)

A Large Deletion With a Large Impact: Homozygous 5,600 bp Deletion of the <i>GALNT3</i> Gene Causing Hyperphosphatemic Tumoral Calcinosis. [PDF]

Kidney Med
Portmann JM, Martini K, Bahr A, Ritter A, Wagner CA, Seeger H.   +5 more
europepmc   +1 more source

Parathyroidectomy reduces the costs of medication in patients with secondary hyperparathyroidism. [PDF]

Clinics (Sao Paulo)
Pereira GMD, Liao M, Arap SS, Magnabosco FF, Brescia MDG, Moyses RMA, Custódio MR, Jorgetti V, Kowalski LP, Montenegro FLM.   +9 more
europepmc   +1 more source

Effects of the novel sodium-dependent phosphate cotransporter 2b inhibitor DZ1462 on hyperphosphatemia in chronic kidney disease. [PDF]

Am J Transl Res
Lu X, Yu LZ, Guo QL, Zhang L, Jiang SX.
europepmc   +1 more source

Hyperphosphatemia as a potential risk factor for arteriovenous fistula dysfunction: A retrospective study in hemodialysis patients. [PDF]

PLoS One
Jiang Y, Cui C, Nan H, Chang T, Li F, Zhang S.   +5 more
europepmc   +1 more source

Case Report: Psychogenic purpura in a uremic patient on peritoneal dialysis. [PDF]

Front Immunol
Zhang L, Zhang H, Zhao Y, Zhang T, Zhu Z, Qiao Y, Tian Y, Su H, Li J, Yang B.   +9 more
europepmc   +1 more source

Exploring the top 30 drugs associated with drug-induced constipation based on the FDA adverse event reporting system. [PDF]

Front Pharmacol
Li W, Liu C, Zhang Z, Cai Z, Lv T, Zhang R, Zuo Y, Chen S.   +7 more
europepmc   +1 more source

Sevelamer

Reactions Weekly
Kharsa A, Rout P.
europepmc   +12 more sources

Some of the next articles are maybe not open access.

Related searches:

Sevelamer

Reactions Weekly, 2021
  +9 more sources